A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous system

2023-510299-29-00 Protocol TEM-GBM_001 Phase I and Phase II (Integrated) - First administration to humans Ongoing, recruitment ended

Start 13 Mar 2019 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 3 sites · Protocol TEM-GBM_001

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 27
Countries 1
Sites 3

Glioblastoma multiforme

Key facts

Sponsor
Genenta Science S.p.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
13 Mar 2019 → ongoing
Decision date (initial)
2024-02-28
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2023-510299-29-00
EudraCT number
2018-001404-11
ClinicalTrials.gov
NCT03866109

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Glioblastoma multiforme

VersionLevelCodeTermSystem organ class
20.0 PT 10018336 Glioblastoma 100000004864
20.0 PT 10018337 Glioblastoma multiforme 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Genenta Science S.p.A.

Sponsor organisation
Genenta Science S.p.A.
Address
Via Olgettina 58
City
Milan
Postcode
20132
Country
Italy

Scientific contact point

Organisation
Genenta Science S.p.A.
Contact name
Genenta Science

Public contact point

Organisation
Genenta Science S.p.A.
Contact name
Genenta Science

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ongoing, recruitment ended 27 3
Rest of world 0

Investigational sites

Italy

3 sites · Ongoing, recruitment ended
Ospedale San Raffaele S.r.l.
U.O. Ematologia e Trapianto Midollo Osseo, Via Olgettina 60, 20132, Milan
IRCCS Foundation Istituto Neurologico Carlo Besta
U.O. Neurologia VIII - Neuro-oncologia Molecolare, Via Giovanni Celoria 11, 20133, Milan
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Largo Francesco Vito 1, 00168, Rome

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2019-03-13 2019-04-12 2026-01-30

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-26 Italy Acceptable
2024-02-22
2024-02-28
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-09-09 Italy Acceptable
2024-02-22
2024-09-09